Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations

被引:49
作者
Derks, Sarah [1 ,2 ]
Postma, Cindy [2 ]
Carvalho, Beatriz
Van den Bosch, Sandra M. [1 ]
Moerkerk, Peter T. M. [1 ]
Herman, James G. [3 ]
Weijenberg, Matty P. [3 ,4 ]
de Bruine, Adriaan P. [1 ]
Meijer, Gerrit A. [2 ]
van Engeland, Manon [1 ]
机构
[1] Maastricht Univ, Dept Pathol, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
[3] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Dept Oncol, Baltimore, MD 21231 USA
[4] Maastricht Univ, Dept Epidemiol, GROW Sch Oncol & Dev Biol, NL-6200 MD Maastricht, Netherlands
关键词
D O I
10.1093/carcin/bgm270
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is a complex and heterogeneous disease in which genomic instability and DNA promoter methylation play important roles. The aim of this study was to investigate the relationship between chromosomal instability (CIN), microsatellite instability (MSI) and promoter methylation of CRC-associated genes. Therefore, 71 CRCs were analysed for CIN and MSI by comparative genomic hybridization and the mononucleotide marker BAT-26, respectively. Promoter methylation of the tumour suppressor and DNA repair genes hMLH1, O-6-MGMT, APC, p14(ARF), p16(INK4A), RASSF1A, GATA-4, GATA-5 and CHFR was analysed using methylation-specific polymerase chain reaction. These integrative analyses showed that in CIN+ CRCs, promoter methylation of GATA-4 and p16(INK4A) was inversely related to chromosomal loss at 15q11-q21 and gain at 20q13, respectively (P values: 3.8 x 10(-2) and 4.5 x 10(-2), respectively). Interestingly, promoter methylation of RASSF1A, GATA-4, GATA-5 and CHFR, as well as a high methylation index (MI), was positively related to chromosomal gain at 8q23-qter (P values: 1.5 x 10(-2), 3.8 x 10(-2), 3.9 x 10(-2), 4.9 x 10(-2) and 8.2 x 10(-3), respectively). MSI was associated with BRAF mutation, promoter methylation of hMLH1, APC and p16(INK4A) and a high MI (total number of methylated genes) (P values: 2.4 x 10(-2), 2.5 x 10(-3), 1.8 x 10(-2), 4.6 x 10(-2) and 1.0 x 10(-2), respectively). Therefore, we conclude that promoter methylation of pivotal tumour suppressor and DNA repair genes is associated with specific patterns of chromosomal changes in CRC, which are different from methylation patterns in MSI tumours.
引用
收藏
页码:434 / 439
页数:6
相关论文
共 57 条
[1]   GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer [J].
Akiyama, Y ;
Watkins, N ;
Suzuki, H ;
Jair, KW ;
van Engeland, M ;
Esteller, M ;
Sakai, H ;
Ren, CY ;
Yuasa, Y ;
Herman, JG ;
Baylin, SB .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (23) :8429-8439
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   Chfr inactivation is not associated to chromosomal instability in colon cancers [J].
Bertholon, J ;
Wang, Q ;
Falette, N ;
Verny, C ;
Auclair, J ;
Chassot, C ;
Navarro, C ;
Saurin, JC ;
Puisieux, A .
ONCOGENE, 2003, 22 (55) :8956-8960
[4]   CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype [J].
Brandes, JC ;
van Engeland, M ;
Wouters, KAD ;
Weijenberg, MP ;
Herman, JG .
CARCINOGENESIS, 2005, 26 (06) :1152-1156
[5]   Myc represses transcription through recruitment of DNA methyltransferase corepressor [J].
Brenner, C ;
Deplus, R ;
Didelot, C ;
Loriot, A ;
Viré, E ;
De Smet, C ;
Gutierrez, A ;
Danovi, D ;
Bernard, D ;
Boon, T ;
Pelicci, PG ;
Amati, B ;
Kouzarides, T ;
de Launoit, Y ;
Di Croce, L ;
Fuks, F .
EMBO JOURNAL, 2005, 24 (02) :336-346
[6]   High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides [J].
Carvalho, B ;
Ouwerkerk, E ;
Meijer, GA ;
Ylstra, B .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (06) :644-646
[7]  
Cunningham JM, 1998, CANCER RES, V58, P3455
[8]  
Derks S, 2004, CELL ONCOL, V26, P291
[9]  
Derks S, 2006, CELL ONCOL, V28, P247
[10]  
Esteller M, 2000, CANCER RES, V60, P4366